Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma
- 1 October 1995
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 55 (4), 223-227
- https://doi.org/10.1111/j.1600-0609.1995.tb00261.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation.Journal of Clinical Oncology, 1992
- Modern chemotherapeutic regimens in the management of aggressive non-Hodgkin lymphoma: Can they be improved?European Journal of Cancer and Clinical Oncology, 1991
- Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease.Journal of Clinical Oncology, 1991
- Methyl-Gag, Ifosfamide, Methotrexate and Etoposide (Mime) as Salvage Therapy for Hodgkin's Disease and Non-Hodgkin's LymphomaActa Oncologica, 1990
- High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1988
- Results of a new combination chemotherapy (etoposid-ifosphamide-mitoxantrone) in advanced NHLZeitschrift für Krebsforschung und Klinische Onkologie, 1986
- Ifosfamide and etoposide as salvage therapy for non‐Hodgkin's lymphomaScandinavian Journal of Haematology, 1986
- IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapyBlood, 1982
- PREVENTION OF ISOPHOSPHAMIDE-INDUCED UROTHELIAL TOXICITY WITH 2-MERCAPTOETHANE SULPHONATE SODIUM (MESNUM) IN PATIENTS WITH ADVANCED CARCINOMAThe Lancet, 1980
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958